Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2014
06/10/2014CA2705836C Treatment of oral pharyngeal dysphagia
06/10/2014CA2704780C Method of treating vitamin b12 deficiency
06/10/2014CA2689639C Solid pharmaceutical dosage form
06/10/2014CA2673183C Bicyclic pyrimidinones and uses thereof
06/10/2014CA2668320C Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
06/10/2014CA2668316C Use of testosterone and a 5-ht1a agonist in the treatment of sexual dysfunction
06/10/2014CA2667091C Method for correcting a lipid imbalance in a subject
06/10/2014CA2663116C Inhibitors of bruton's tyrosine kinase
06/10/2014CA2656966C A topical analgesic composition
06/10/2014CA2656239C Composition and methods for the enterosorption and management of toxins
06/10/2014CA2654334C Antitumoral dihydropyran-2-one compounds
06/10/2014CA2647982C Solid pharmaceutical preparation containing tramadol
06/10/2014CA2639895C Energizing compositions comprising goji, red clover and polygonum multiflorum, and uses thereof
06/10/2014CA2635205C Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
06/10/2014CA2634056C Amorphous form of 1,2-dihydropyridine compound
06/10/2014CA2612090C Tablet containing hardly soluble active ingredient
06/10/2014CA2606386C Therapeutic compositions
06/10/2014CA2602474C Hydrogenated benzo (c) thiophene derivatives as immunomodulators
06/10/2014CA2601895C Amino acid composition for improving glucose tolerance
06/10/2014CA2601278C Prevention of retinopathy by inhibition of the visual cycle
06/10/2014CA2594407C Device method, and use for treatment of neuropathy involving nitric oxide
06/10/2014CA2566741C Acyclovir formulations
06/10/2014CA2562871C Iron based compounds for elastogenesis and connective tissue treatment
06/10/2014CA2559740C Thiadiazolidinones as gsk-3 inhibitors
06/10/2014CA2557857C Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation
06/10/2014CA2541509C Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
06/10/2014CA2530037C Podophyllotoxin derivatives
06/10/2014CA2482634C Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signal transduction
06/10/2014CA2459816C Hybrid and tandem expression of neisserial proteins
06/10/2014CA2441287C Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
06/10/2014CA2376607C System for exsanguinous metabolic support of an organ or tissue
06/10/2014CA2361268C A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
06/06/2014CA2813934A1 Polymorphs of cddo ethyl ester and uses thereof
06/05/2014WO2014085795A1 Mixed lineage kinase inhibitors for hiv/aids therapies
06/05/2014WO2014085791A2 Compositions and uses thereof for treating multiple myeloma
06/05/2014WO2014085684A1 Gastric health supplement and methods thereof
06/05/2014WO2014085668A1 Anticonvulsant activity of steroids
06/05/2014WO2014085652A1 Targeting cancer with metabolic therapy and hyperbaric oxygen
06/05/2014WO2014085633A1 Substituted biaryl sulfonamides and the use thereof
06/05/2014WO2014085623A1 Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
06/05/2014WO2014085613A1 Hydroxytyrosol and oleuropein compositions for induction of dna damage, cell death and lsd1 inhibition
06/05/2014WO2014085607A1 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
06/05/2014WO2014085600A1 Neuroprotective agents for treatment of neurodegenerative diseases
06/05/2014WO2014085545A1 Methods and compositions involving rad51 inhibitors
06/05/2014WO2014085528A1 Azaquinazoline carboxamide derivatives
06/05/2014WO2014085526A1 Stabilized vancomycin formulations
06/05/2014WO2014085518A1 Controlled release compositions and methods of using
06/05/2014WO2014085494A1 Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
06/05/2014WO2014085491A2 Bryoid compositions, methods of making and use thereof
06/05/2014WO2014085489A1 Inhibitor of apoptosis protein (iap) antagonists
06/05/2014WO2014085485A1 Methods and compositions for targeting cancer stem cells
06/05/2014WO2014085480A1 Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
06/05/2014WO2014085474A1 Treatment of pulmonary disease
06/05/2014WO2014085453A2 Small molecule lxr inverse agonists
06/05/2014WO2014085437A2 Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
06/05/2014WO2014085413A1 Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators
06/05/2014WO2014085381A1 Pharmaceutical combinations
06/05/2014WO2014085371A1 Novel pharmaceutical composition
06/05/2014WO2014085367A1 Substituted benztropine analogs for treatment of dementia
06/05/2014WO2014085362A1 Methods for the treatment of parkinson's disease psychosis using pimavanserin
06/05/2014WO2014085318A1 Combination therapy
06/05/2014WO2014085284A1 Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
06/05/2014WO2014085225A1 Pyrimidine compounds for the treatment of cancer
06/05/2014WO2014085211A2 Spirocyclic sulfones as gamma secretase inhibitors
06/05/2014WO2014085210A1 Inhibitors of the renal outer medullary potassium channel
06/05/2014WO2014085208A1 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
06/05/2014WO2014085153A1 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
06/05/2014WO2014084944A1 Boronic and borinic acid compounds as inhibitors of sulfenic acid-containing proteins
06/05/2014WO2014084778A1 Pyrimidine-2,4-diamine derivatives for treatment of cancer
06/05/2014WO2014084744A1 Saccharide dendritic cluster compounds as inhibitors of bace-1
06/05/2014WO2014084670A1 Composition of external application to skin
06/05/2014WO2014084669A1 Pharmaceutical composition for preventing or treating osteoporosis, containing praeruptorin a or pharmaceutically acceptable salt thereof as active ingredient
06/05/2014WO2014084658A1 Composition for preventing or treating heart disease
06/05/2014WO2014084651A1 A stabilized pemetrexed formulation
06/05/2014WO2014084572A1 Catechin bioavailability enhancer comprising cyclodextrin
06/05/2014WO2014084568A1 Topical gel composition containing dexibuprofen emulsion with enhanced permeability
06/05/2014WO2014084508A1 Composition for stabilizing fusion protein in which protein and fc domain are fused
06/05/2014WO2014084494A1 Novel disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient
06/05/2014WO2014084471A1 Novel n-acetyl-l-leucyl-l-leucyl-l-norleucinal (alln) derivative compound, composition for preventing or treating malaria, containing same as active ingredient, and use thereof
06/05/2014WO2014084434A1 Composition for preventing and treating rotator cuff injury, containing cyanidin or delphinidin as active ingredient
06/05/2014WO2014084433A1 Composition comprising peroxisome proliferator-activated receptor delta agonist, as active ingredient, for promoting treatment of myocardial injury after myocardial infraction
06/05/2014WO2014084430A1 Combination anti-cancer therapy
06/05/2014WO2014084427A1 Composition comprising alginic acid for preventing or treating osteoarthritis
06/05/2014WO2014084401A1 Medical patch
06/05/2014WO2014084378A1 Anticancer drug comprising cyclic rgd sequence-containing peptide
06/05/2014WO2014084330A1 Nitrogen-containing heterocyclic compound
06/05/2014WO2014084312A1 Imidazopyridine compound
06/05/2014WO2014084311A1 Ropinirole-containing adhesive patch
06/05/2014WO2014084298A1 Lsd1-selective inhibitor having lysine structure
06/05/2014WO2014084246A1 Inhibitor of nucleic acid for regulating activity of rnai molecule
06/05/2014WO2014084085A1 Prophylactic/therapeutic agent for hearing disorder or cerebellar ataxia
06/05/2014WO2014083613A1 Peritoneal dialysis fluid
06/05/2014WO2014083612A1 Peritoneal dialysis fluid
06/05/2014WO2014083567A2 Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
06/05/2014WO2014083557A1 Compositions for the treatment of rosacea
06/05/2014WO2014083554A1 Stable amorphous form of linagliptin
06/05/2014WO2014083529A1 Heterocyclic compounds as inhibitors of the sodium iodide symporter
06/05/2014WO2014083522A1 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia
06/05/2014WO2014083432A2 Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
06/05/2014WO2014083327A1 Adenine derivatives suitable for the treatment of (inter alia) muscular dystrophy
1 ... 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 ... 7860